These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 21178332)

  • 1. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
    Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
    Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
    Saeger W; Lüdecke B; Lüdecke DK
    Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Markers of proliferation and invasiveness in somatotropinomas.
    Baldys-Waligorska A; Wierzbicka I; Sokolowski G; Adamek D; Golkowski F
    Endokrynol Pol; 2018; 69(2):182-189. PubMed ID: 29334118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathobiology of pituitary adenomas and carcinomas.
    Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
    Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
    Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
    Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
    Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
    Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications.
    Jaffrain-Rea ML; Angelini M; Gargano D; Tichomirowa MA; Daly AF; Vanbellinghen JF; D'Innocenzo E; Barlier A; Giangaspero F; Esposito V; Ventura L; Arcella A; Theodoropoulou M; Naves LA; Fajardo C; Zacharieva S; Rohmer V; Brue T; Gulino A; Cantore G; Alesse E; Beckers A
    Endocr Relat Cancer; 2009 Sep; 16(3):1029-43. PubMed ID: 19556287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A classification tree approach for pituitary adenomas.
    Righi A; Agati P; Sisto A; Frank G; Faustini-Fustini M; Agati R; Mazzatenta D; Farnedi A; Menetti F; Marucci G; Foschini MP
    Hum Pathol; 2012 Oct; 43(10):1627-37. PubMed ID: 22446019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families.
    Daly AF; Vanbellinghen JF; Khoo SK; Jaffrain-Rea ML; Naves LA; Guitelman MA; Murat A; Emy P; Gimenez-Roqueplo AP; Tamburrano G; Raverot G; Barlier A; De Herder W; Penfornis A; Ciccarelli E; Estour B; Lecomte P; Gatta B; Chabre O; Sabaté MI; Bertagna X; Garcia Basavilbaso N; Stalldecker G; Colao A; Ferolla P; Wémeau JL; Caron P; Sadoul JL; Oneto A; Archambeaud F; Calender A; Sinilnikova O; Montañana CF; Cavagnini F; Hana V; Solano A; Delettieres D; Luccio-Camelo DC; Basso A; Rohmer V; Brue T; Bours V; Teh BT; Beckers A
    J Clin Endocrinol Metab; 2007 May; 92(5):1891-6. PubMed ID: 17244780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between SPARC (Osteonectin) expression with immunophenotypical and invasion characteristics of pituitary adenomas.
    Onoz M; Basaran R; Gucluer B; Isik N; Kaner T; Sav A; Elmaci I
    APMIS; 2015 Mar; 123(3):199-204. PubMed ID: 25556322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior ?
    Yarman S; Kurtulmus N; Canbolat A; Bayindir C; Bilgic B; Ince N
    Neuro Endocrinol Lett; 2010; 31(6):823-8. PubMed ID: 21196926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
    Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas.
    Leontiou CA; Gueorguiev M; van der Spuy J; Quinton R; Lolli F; Hassan S; Chahal HS; Igreja SC; Jordan S; Rowe J; Stolbrink M; Christian HC; Wray J; Bishop-Bailey D; Berney DM; Wass JA; Popovic V; Ribeiro-Oliveira A; Gadelha MR; Monson JP; Akker SA; Davis JR; Clayton RN; Yoshimoto K; Iwata T; Matsuno A; Eguchi K; Musat M; Flanagan D; Peters G; Bolger GB; Chapple JP; Frohman LA; Grossman AB; Korbonits M
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2390-401. PubMed ID: 18381572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
    Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
    Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations.
    Jaffrain-Rea ML; Rotondi S; Turchi A; Occhi G; Barlier A; Peverelli E; Rostomyan L; Defilles C; Angelini M; Oliva MA; Ceccato F; Maiorani O; Daly AF; Esposito V; Buttarelli F; Figarella-Branger D; Giangaspero F; Spada A; Scaroni C; Alesse E; Beckers A
    Endocr Relat Cancer; 2013 Oct; 20(5):753-66. PubMed ID: 23940012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
    Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
    Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
    Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
    Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
    Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
    Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD147 expression in pituitary adenomas and its significance for clinical outcome.
    Qu X; Yang W; Jiang M; Han T; Han L; Qu Y; Wang G; Shi D; Xu G
    Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
    Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
    PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.